Vernalis receives 1.5m dollar payment through Genentech collaboration

AIM-listed pharmaceuticals company Vernalis has received a 1.5m dollar payment under its drug discovery collaboration with Genentech, a member of the Roche group.

The collaboration, which commenced in January 2012, aims to discover novel small molecules against an undisclosed target utilising Vernalis' fragment and structure-based drug discovery platform.

Ian Garland, Chief Executive Officer of Vernalis, commented: "We are delighted to have achieved this success milestone under our collaboration with Genentech which further endorses the quality of our research group's work."

Article continues below

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Vernalis' share price was up 1.59% to 24p at 11:38 on Monday.

Vernalis develops and commercialises low-risk late stage products for unmet medical need.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.